WT1 and acute myeloid leukemia: Our results describe a single-center experience of a phase I/II study of first-in-human WT1 protein-based vaccination (WT1-A10 + AS01B) in patients with AML in complete remission with incomplete blood count recovery or partial remission post-induction therapy.